Tarveda Therapeutics Stock
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.
Sign up today and learn more about Tarveda Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Tarveda Therapeutics Stock
Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.
Executive Vice President, Drug Discovery
Stephen J. Lippard
Associate Director; Analytical and Formulation Development
President and Chief Executive Officer
Chief Scientific Officer
Chief Medical Officer
Member Board Of DirectorsMember
Executive Vice President, Strategy